Siewert Type 1 GEJ Cancer clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for

  • Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

    Sorry, in progress, not accepting new patients

    This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.

    Santa Monica 5393212, California 5332921 and other locations

Last updated: